Chikungunya Virus Infection in Traveler to Australia

To the Editor: Chikungunya is a mosquito-borne alphavirus in the family Togaviridae. Recently, a chikungunya virus epidemic that affected thousands of persons occurred in islands in the southwestern Indian Ocean, including Mauritius and Reunion (1). An outbreak is ongoing in India, and cases are being exported to many other countries (2–4). The likelihood of importation of exotic infectious agents into Australia increased during events such as the March 2006 Commonwealth Games in Melbourne. Urgent diagnosis of rarely seen infections is a travel health challenge, particularly when serologic tests used for diagnosis in areas with high prevalence are not locally available. Only 1 previously diagnosed case of chikungunya virus infection has been reported in Australia; it involved importation of the virus from Indonesia to Darwin in 1989 (5). We report a second case of infection with this virus.

A 59-year-old man came to a hospital emergency department in North Melbourne, Australia, on March 12, 2006, 5 days after traveling from Mauritius for the Commonwealth Games. He reported a 2-day history of acute swelling and erythema of the left leg and associated malaise. Twenty-four hours earlier, severe lumbar back pain and arthralgias that involved the lower limbs had developed, with associated fevers, rigors, and headache.

The patient had a temperature of 39°C, bilateral conjunctivitis, tender and markedly swollen Achilles tendons, a swollen left ankle, and a maculopapular rash that involved the left forefoot and anterior portion of the shin. Initial blood examinations showed leukopenia (leukocyte count 1.8 × 10^9/L), lymphocyte count 0.2 × 10^9/L), mild thrombocytopenia (platelet count 105 × 10^9/L), and abnormal liver function test results (alanine aminotransferase 133 IU/mL, γ-glutamyl transpeptidase 141 IU/mL, bilirubin 7 mmol/L). Malaria blood films and dengue serologic results were negative. A validated, in-house, generic alphavirus reverse transcription–PCR (RT-PCR) showed positive results 24 hours after collection of blood when the patient was admitted.

The patient received supportive treatment and was discharged from the hospital 3 days after admission, at which time leukopenia and thrombocytopenia had improved. The patient had fully recovered on review 1 week after discharge.

For virus isolation, plasma and leukocyte fractions were placed onto Vero E6 cells and incubated at 37°C for 5 days. Cells were observed daily for virus-specific cytopathic effects. A virus isolate was obtained after 4 days of cell culture. A 10-ML volume of supernatant from infected cells was obtained after 4 days of cell culture. A 10-ML volume of supernatant from infected cells was applied to a carbon-coated grid, stained with phototungstic acid, and examined by electron microscopy. This procedure showed virus with morphology similar to Togavirus (data not shown).

Chikungunya virus was identified by a heminested RT-PCR for the non-
structural protein 4 gene. First-round primers were AlphaF1 (GenBank accession no. NC004162, nt 6942–6961, 5′-CAGTAATGGAARTC HGGHATG-3′) and AlphaR (nt 7121–7141, 5′-CTTTGAGGACCRC GTASAG-3′). Second-round primers were AlphaF2 (nt 7480–7501) (5′-CGTASAG-3′ and the local community. chikungunya virus is commonly spread by mosquitoes of the genera Aedes, including Aedes aegypti, Aedes furcifer-taylori, Aedes luteocephalus, Aedes albopictus, and Aedes dalzieli (7). The Australian Ross River and Barmah Forest alphaviruses are spread by many species of Aedes and Culex (8). Because some local species could transmit chikungunya virus, necessary steps should be taken to ensure containment when a patient is viremic.

This case highlights the potential for exotic viruses to be introduced into Australia by visitors or returning travelers and the utility of molecular testing for their rapid detection. The generic nature of the RT-PCR enabled detection of an alphavirus with subsequent specific identification by sequencing. Rapid identification and differentiation in a public health setting minimized the potential for spread of the virus.

JULIAN D. DRUCE,* DOUGLAS F. JOHNSON,† THOMAS TRAN,* MICHAEL J. RICHARDS,† and CHRISTOPHER J. BIRCH*

*Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia; and †Royal Melbourne Hospital, Parkville, Melbourne, Victoria, Australia

References


Address for correspondence: Julian D. Druce, Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn St, North Melbourne, Victoria 3051, Australia, email: julian.druce@mh.org.au

Avian Influenza A (H5N1) Age Distribution in Humans

To the Editor: A total of 229 confirmed human cases of avian influenza A (H5N1) were reported to the World Health Organization (WHO) from 10 countries of Africa, Asia, and Europe in the 30 months leading up to July 4, 2006 (1). WHO has highlighted the skewed age distribution of these confirmed cases toward children and young adults, with relatively few cases in older age categories (2). An explanation for this age bias is currently lacking, although a range of behavioral, biological, demographic, and data-related factors may account for the observed pattern (2,3).

To determine whether the statistical parameters of the case distribution can shed any light on the issue, we reviewed the age profile of patients with confirmed avian influenza A